These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31310855)

  • 1. Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial.
    Sharma A; Hagström E; Wojdyla DM; Neely ML; Harrington RA; Wallentin L; Alexander JH; Goodman SG; Lopes RD;
    Am Heart J; 2019 Sep; 215():106-113. PubMed ID: 31310855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial.
    Hess CN; James S; Lopes RD; Wojdyla DM; Neely ML; Liaw D; Hagstrom E; Bhatt DL; Husted S; Goodman SG; Lewis BS; Verheugt FWA; De Caterina R; Ogawa H; Wallentin L; Alexander JH
    J Am Coll Cardiol; 2015 Aug; 66(7):777-787. PubMed ID: 26271059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apixaban with antiplatelet therapy after acute coronary syndrome.
    Alexander JH; Lopes RD; James S; Kilaru R; He Y; Mohan P; Bhatt DL; Goodman S; Verheugt FW; Flather M; Huber K; Liaw D; Husted SE; Lopez-Sendon J; De Caterina R; Jansky P; Darius H; Vinereanu D; Cornel JH; Cools F; Atar D; Leiva-Pons JL; Keltai M; Ogawa H; Pais P; Parkhomenko A; Ruzyllo W; Diaz R; White H; Ruda M; Geraldes M; Lawrence J; Harrington RA; Wallentin L;
    N Engl J Med; 2011 Aug; 365(8):699-708. PubMed ID: 21780946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome.
    Khan R; Lopes RD; Neely ML; Stevens SR; Harrington RA; Diaz R; Cools F; Jansky P; Montalescot G; Atar D; Lopez-Sendon J; Flather M; Liaw D; Wallentin L; Alexander JH; Goodman SG;
    Heart; 2015 Sep; 101(18):1475-84. PubMed ID: 26109589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
    Connors JM; Brooks MM; Sciurba FC; Krishnan JA; Bledsoe JR; Kindzelski A; Baucom AL; Kirwan BA; Eng H; Martin D; Zaharris E; Everett B; Castro L; Shapiro NL; Lin JY; Hou PC; Pepine CJ; Handberg E; Haight DO; Wilson JW; Majercik S; Fu Z; Zhong Y; Venugopal V; Beach S; Wisniewski S; Ridker PM;
    JAMA; 2021 Nov; 326(17):1703-1712. PubMed ID: 34633405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38).
    Hochholzer W; Wiviott SD; Antman EM; Contant CF; Guo J; Giugliano RP; Dalby AJ; Montalescot G; Braunwald E
    Circulation; 2011 Jun; 123(23):2681-9. PubMed ID: 21606391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
    Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
    Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
    Lopes RD; Heizer G; Aronson R; Vora AN; Massaro T; Mehran R; Goodman SG; Windecker S; Darius H; Li J; Averkov O; Bahit MC; Berwanger O; Budaj A; Hijazi Z; Parkhomenko A; Sinnaeve P; Storey RF; Thiele H; Vinereanu D; Granger CB; Alexander JH;
    N Engl J Med; 2019 Apr; 380(16):1509-1524. PubMed ID: 30883055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.
    Lopes RD; Vora AN; Liaw D; Granger CB; Darius H; Goodman SG; Mehran R; Windecker S; Alexander JH
    Am Heart J; 2018 Jun; 200():17-23. PubMed ID: 29898844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
    Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
    Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial.
    Cornel JH; Lopes RD; James S; Stevens SR; Neely ML; Liaw D; Miller J; Mohan P; Amerena J; Raev D; Huo Y; Urina-Triana M; Gallegos Cazorla A; Vinereanu D; Fridrich V; Harrington RA; Wallentin L; Alexander JH;
    Am Heart J; 2015 Apr; 169(4):531-8. PubMed ID: 25819860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
    Hermiller JB; Krucoff MW; Kereiakes DJ; Windecker S; Steg PG; Yeh RW; Cohen DJ; Cutlip DE; Massaro JM; Hsieh WH; Mauri L;
    JACC Cardiovasc Interv; 2016 Jan; 9(2):138-47. PubMed ID: 26793956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Kopin D; Jones WS; Sherwood MW; Wojdyla DM; Wallentin L; Lewis BS; Verheugt FWA; Vinereanu D; Bahit MC; Halvorsen S; Huber K; Parkhomenko A; Granger CB; Lopes RD; Alexander JH
    Am Heart J; 2018 Mar; 197():133-141. PubMed ID: 29447773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
    Yeh RW; Secemsky EA; Kereiakes DJ; Normand SL; Gershlick AH; Cohen DJ; Spertus JA; Steg PG; Cutlip DE; Rinaldi MJ; Camenzind E; Wijns W; Apruzzese PK; Song Y; Massaro JM; Mauri L;
    JAMA; 2016 Apr; 315(16):1735-49. PubMed ID: 27022822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
    Moll F; Baumgartner I; Jaff M; Nwachuku C; Tangelder M; Ansel G; Adams G; Zeller T; Rundback J; Grosso M; Lin M; Mercur MF; Minar E;
    J Endovasc Ther; 2018 Apr; 25(2):158-168. PubMed ID: 29552984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
    Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L;
    JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel.
    Widimsky P; Motovska Z; Bolognese L; Dudek D; Hamm C; Tanguay JF; Ten Berg J; Brown E; LeNarz L; Miller DL; Montalescot G;
    Heart; 2015 Aug; 101(15):1219-24. PubMed ID: 26060122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.